IMbrave150: A randomised phase III study of atezolizumab 1 bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

被引：0
|
作者：
Qin, S. [1 ]
Cheng, A-L. [2 ]
Ducreux, M. P. [3 ]
Galle, P. R. [4 ]
Zhu, A. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Ikeda, M. [10 ]
机构：
[1] Peoples Liberat Army 81 Hosp, Ctr Canc, Nanjing, Jiangsu, Peoples R China
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Gustave Roussy, Gastrointestinal Unit, Villejuif, France
[4] Univ Med Mainz, Dept Internal Med, Mainz, Germany
[5] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[6] Seoul Natl Univ, Med Oncol Ctr, Coll Med, Seoul, South Korea
[7] F Hoffmann La Roche Ltd, Prod Dev Oncol, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Geffen Sch Med, Los Angeles, CA 90024 USA
[10] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
210TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150
    Ducreux, M. P.
    Cheng, A-L.
    Qin, S.
    Zhu, A. X.
    Ikeda, M.
    Kim, T-Y.
    Xu, D-Z.
    Verret, W.
    Liu, J.
    Finn, R. S.
    Galle, P. R.
    ANNALS OF ONCOLOGY, 2018, 29 : 267 - 267
  • [2] IMbrave150: A randomized phase III study of 1L atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma.
    Finn, Richard S.
    Ducreux, Michel
    Qin, Shukui
    Galle, Peter R.
    Zhu, Andrew X.
    Ikeda, Masafumi
    Kim, Tae-You
    Xu, Derek-Zhen
    Verret, Wendy
    Liu, Juan
    Grossman, William
    Cheng, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study
    Ducreux, Michel
    Zhu, Andrew
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Verret, Wendy
    Xu, Zhen
    Hernandez, Sairy
    Liu, Juan
    Shao, Hui
    Huang, Chen
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S121
  • [4] Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150
    Li, D.
    Toh, H.
    Merle, P.
    Tsuchiya, K.
    Hernandez, S.
    Shao, H.
    Mulla, S.
    Ding, B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S234 - S234
  • [5] Updated Efficacy and Safety Data from IMbrave150: Atezolizumab Plus Bevacizumab vs. Sorafenib for Unresectable Hepatocellular Carcinoma
    Roy, Akash
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2022, 12 (06) : 1575 - 1576
  • [6] Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
    Kudo, Masatoshi
    Finn, Richard S.
    Cheng, Ann-Lii
    Zhu, Andrew X.
    Ducreux, Michel
    Galle, Peter R.
    Sakamoto, Naoya
    Kato, Naoya
    Nakano, Michitaka
    Jia, Jing
    Vogel, Arndt
    LIVER CANCER, 2023, 12 (05) : 479 - 493
  • [7] Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma
    Cheng, Ann-Lii
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed O.
    Li, Daneng
    Verret, Wendy
    Ma, Ning
    Nicholas, Alan
    Wang, Yifan
    Li, Lindong
    Zhu, Andrew X.
    Finn, Richard S.
    JOURNAL OF HEPATOLOGY, 2022, 76 (04) : 862 - 873
  • [8] Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma
    Kaseb, Ahmed O.
    Guan, Yinghui
    Yavuz, Betul Gok
    Abbas, Alexander R.
    Lu, Shan
    Hasanov, Elshad
    Toh, Han Chong
    Verret, Wendy
    Wang, Yulei
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2022, 9 : 1065 - 1079
  • [9] Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
    Salem, Riad
    Li, Daneng
    Sommer, Nicolas
    Hernandez, Sairy
    Verret, Wendy
    Ding, Beiying
    Lencioni, Riccardo
    CANCER MEDICINE, 2021, 10 (16): : 5437 - 5447
  • [10] Atezolizumab (ATEZO) plus Bevacizumab ( BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150
    Galle, Peter R.
    Cheng, Ann-Lll
    Qin, Shukui
    Ikeda, Masafumi
    Ducreux, Michel
    Zhu, Andrew
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Verret, Wendy
    Xu, Derek
    Hernandez, Sairy
    Liu, Juan
    Shao, Hui
    Mulla, Sohail
    Lim, Hy
    Finn, Richard
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 220 - 220
12345